½ðºÌÓéÀÖ³Ç

Acquisitions of own shares

In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, ½ðºÌÓéÀֳǠSA/NV (¡°½ðºÌÓéÀֳǡ± or the ¡°Company) (Euronext Brussels: ½ðºÌÓéÀÖ³Ç) hereby discloses certain information in relation to its Share Repurchase Program 2020.

Under this program, ½ðºÌÓéÀÖ³Ç has requested a financial intermediary to repurchase up to 1.2 million ½ðºÌÓéÀÖ³Ç shares on its behalf under the terms of a discretionary mandate agreement with initial validity until 15 June 2020, effective as from 25 March 2020, to cover current and future obligations under ½ðºÌÓéÀÖ³Ç's Long Term Incentive Plans for its personnel. The validity of this agreement has been extended to 30 September 2020.

In the framework of this Share Repurchase Program 2020, ½ðºÌÓéÀÖ³Ç repurchased 178 242 ½ðºÌÓéÀÖ³Ç shares on Euronext Brussels in the period from 31 July 2020 up to and including 5 August 2020, as follows:

As a result thereof, the Share Repurchase Program 2020 has been completed.
 

Disposals of own shares
In accordance with article 8:6 of the Royal Decree executing the Belgian Code of Companies and Associations, ½ðºÌÓéÀֳǠannounces that, following exercises of stock options by members of its personnel, it has disposed of ½ðºÌÓéÀÖ³Ç shares OTC in view of deliveries of these shares to the relevant members of the personnel, within the framework of the Long Term Incentive Program of the ½ðºÌÓéÀÖ³Ç Group, as follows:

This press release is available on ½ðºÌÓéÀֳǠSA/NV¡¯s website via the following link.

Investor relations

Antje Witte
Investor Relations, ½ðºÌÓéÀÖ³Ç
T +32 2 559 94 14
antje.witte@ucb.com

Isabelle Ghellynck
Investor Relations, ½ðºÌÓéÀÖ³Ç
T +32 2 559 95 88
isabelle.ghellynck@ucb.com
 

About ½ðºÌÓéÀÖ³Ç

½ðºÌÓéÀÖ³Ç, Brussels, Belgium () is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With 7 500 people in approximately 40 countries, the company generated revenue of € 4.9 billion in 2019. ½ðºÌÓéÀÖ³Ç is listed on Euronext Brussels (symbol: ½ðºÌÓéÀÖ³Ç). Follow us on Twitter: @½ðºÌÓéÀÖ³Ç_news